Press Releases

30-05-2023

Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA

MORE >

15-05-2023

​​​​​​​Reorganization in the Executive Board of Eckert & Ziegler

MORE >

11-05-2023

Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023

MORE >

08-05-2023

Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate

MORE >

25-04-2023, 17:59 CEST (Ad hoc press release)

Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance

MORE >

20-04-2023

Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177

MORE >

12-04-2023

Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site

MORE >

04-04-2023

Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

MORE >

30-03-2023

​​​​​Eckert & Ziegler: Successful fiscal year 2022

MORE >

24-03-2023

​​​​​​​Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)

MORE >

23-03-2023

Eckert & Ziegler with Unchanged Dividend Proposal

MORE >

03-03-2023

Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.

MORE >

01-02-2023

Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting

MORE >

17-01-2023, 12:47 CET (Ad hoc press release)

Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures

MORE >